Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ligand Pharm Cmn (LGND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,293,234
  • Shares Outstanding, K 20,960
  • Annual Sales, $ 108,970 K
  • Annual Income, $ -1,640 K
  • 36-Month Beta 1.27
  • Price/Sales 20.95
  • Price/Cash Flow 112.71
  • Price/Book 6.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
102.56 +6.68%
on 04/06/17
110.70 -1.17%
on 04/26/17
+4.63 (+4.42%)
since 03/24/17
3-Month
95.08 +15.07%
on 02/24/17
110.70 -1.17%
on 04/26/17
+6.35 (+6.16%)
since 01/26/17
52-Week
87.50 +25.04%
on 11/04/16
139.79 -21.73%
on 08/01/16
-16.65 (-13.21%)
since 04/26/16

Most Recent Stories

More News
Ligand to Report First Quarter 2017 Results on May 9th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2017 financial results on May 9, 2017. Ligand's CEO John Higgins, President and COO Matt Foehr...

LGND : 109.41 (+0.47%)
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the OmniAb(R) Technology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that CNA Development LLC, an affiliate of Janssen Pharmaceuticals, Inc. (Janssen) has filed an IND for an antibody discovered...

LGND : 109.41 (+0.47%)
Ligand to Participate in Upcoming Investor Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conference:

LGND : 109.41 (+0.47%)
New Strong Sell Stocks for March 7th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

GEN : 2.42 (unch)
LGND : 109.41 (+0.47%)
AMBA : 55.44 (-0.72%)
GCP : 33.25 (-0.45%)
CTO : 55.47 (-1.09%)
Look for Shares of Ligand Pharmaceuticals to Potentially Pullback after Yesterday's 4.60% Rise

Ligand Pharmaceuticals (NASDAQ:LGND) traded in a range yesterday that spanned from a low of $99.29 to a high of $105.60. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day...

LGND : 109.41 (+0.47%)
Enrollment Completed in Ligand's Phase 2 Trial of LGD-6972 in Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company's Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist...

LGND : 109.41 (+0.47%)
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates

Ligand Pharmaceuticals Incorporated (LGND) reported fourth-quarter 2016 earnings of 50 cents per share (including the impact of stock-based compensation expense), down 11.1% from the year-ago figure.

LGND : 109.41 (+0.47%)
NVS : 76.35 (+0.14%)
AMGN : 164.61 (-0.05%)
CLLS : 23.83 (+1.10%)
Ligand Reports Fourth Quarter and Full Year 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and 12 months ended December 31, 2016, and provided an operating forecast and program updates....

LGND : 109.41 (+0.47%)
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More

The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.

LGND : 109.41 (+0.47%)
BMRN : 96.07 (+2.00%)
ZTS : 55.57 (+0.82%)
SAGE : 72.16 (-1.65%)
TEVA : 31.28 (+1.69%)
ICPT : 113.45 (-1.15%)
ALXN : 120.73 (+0.15%)
Forget Alexion, Buy these 4 Biotech Stocks Instead

We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

CELG : 125.20 (-0.25%)
LGND : 109.41 (+0.47%)
EXEL : 22.00 (-0.36%)
FATE : 4.73 (+0.42%)
ALXN : 120.73 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases....

See More

Support & Resistance

2nd Resistance Point 112.40
1st Resistance Point 110.90
Last Price 109.41
1st Support Level 107.71
2nd Support Level 106.02

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.